RxDoctor Payments Data

Roger Hajjar

Cardiovascular Disease · New York, NYNPI 1003801903

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,163,656 of the $5,164,409 with a category attached, or 100.0%. Asklepios Biopharmaceutical Inc. accounts for 88.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $2,429,895 and has fallen 100.0% since, to $21 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,164,409in general payments, 2019–2025

Across 8 payments — averaging $645,551 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Asklepios Biopharmaceutical Inc.$4.5M
  • Bayer$620K
  • Abiomed$732
  • AstraZeneca$21

What the payments were for

  • Travel & lodging$7320%
  • Food & beverage$210%
  • Other$5,163,656100%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Asklepios Biopharmaceutical Inc.2$4,543,973
Bayer1$619,683
Abiomed4$732
AstraZeneca1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,164,409 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →